Core Laboratories (NYSE:CLB) Announces Q4 2026 Earnings Guidance

Key Points

• Core Laboratories guided for fourth-quarter 2026 EPS of $0.12–$0.20, compared with the $0.19 analyst consensus, and revenue of $128.5 million–$134.5 million versus the $134.2 million consensus.
• Shares were down 1.0% to $10.38, near the lower end of their 52-week range of $9.13–$20.36. The company’s latest quarter met EPS expectations at $0.16, while revenue declined 1.8% year over year to $132.08 million.
• Core Laboratories declared a quarterly dividend of $0.01 per share, equivalent to a $0.04 annualized payout and a 0.4% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $21.00.

Core Laboratories (NYSE:CLB - Get Free Report) issued an update on its fourth quarter 2026 earnings guidance on Friday morning. The company provided EPS guidance of 0.120-0.200 for the period, compared to the consensus EPS estimate of 0.190. The company issued revenue guidance of $128.5 million-$134.5 million, compared to the consensus revenue estimate of $134.2 million.

Core Laboratories Trading Down 1.0%

CLB opened at $10.38 on Friday. The firm has a 50 day simple moving average of $11.03 and a 200 day simple moving average of $13.96. Core Laboratories has a fifty-two week low of $9.13 and a fifty-two week high of $20.36. The company has a market cap of $476.33 million, a price-to-earnings ratio of 27.32, a price-to-earnings-growth ratio of 2.09 and a beta of 1.14. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.12 and a quick ratio of 1.55.

Core Laboratories (NYSE:CLB - Get Free Report) last released its quarterly earnings data on Wednesday, October 28th. The oil and gas company reported $0.16 EPS for the quarter, meeting analysts' consensus estimates of $0.16. Core Laboratories had a return on equity of 9.01% and a net margin of 3.42%. The business had revenue of $132.08 million during the quarter, compared to the consensus estimate of $131.87 million. During the same quarter in the prior year, the company posted $0.22 earnings per share. The firm's revenue was down 1.8% on a year-over-year basis. On average, sell-side analysts anticipate that Core Laboratories will post 0.56 earnings per share for the current year.

Core Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Monday, November 9th will be issued a $0.01 dividend. The ex-dividend date is Monday, November 9th. This represents a $0.04 annualized dividend and a yield of 0.4%. Core Laboratories's dividend payout ratio (DPR) is 7.14%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CLB shares. Wall Street Zen raised shares of Core Laboratories from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Johnson Rice raised Core Laboratories from a "hold" rating to a "buy" rating and set a $21.00 price objective on the stock in a research note on Thursday, August 13th. Finally, Weiss Ratings upgraded Core Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $21.00.

About Core Laboratories

Core Laboratories N.V. NYSE: CLB is a global provider of proprietary reservoir description and production enhancement services and products for the energy industry. The company helps oil and natural gas producers evaluate reservoirs, improve well performance, and optimize the recovery of hydrocarbons.

Its reservoir description activities include geological and geochemical analysis, petrophysical services, core and fluid analysis, and laboratory testing used to characterize subsurface formations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.